Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients

Asan Medical Center

Status: Completed

Conditions: Liver Transplantation; Major Adverse Cardiovascular Events

Treatments: Drug: Preoperative Statin Use

Study type: Observational

Funder types: Other

Identifiers

NCT07089589

2025-0645

Details and patient eligibility

About

The goal of this multicenter observational study is to determine whether preoperative statin use reduces major adverse cardiovascular events or other complications after liver transplantation. The main question it aims to answer is:

Does preoperative statin use reduce major adverse cardiovascular events or other complications after liver transplantation? The records of participants who already took statins before liver transplantation will be reviewed.

Full description

Cardiovascular complications have emerged as a leading cause of early postoperative death following liver transplantation (LT), accounting for over 40% of early deaths. As a result, preventing postoperative cardiac complications has become a critical concern in the management of LT recipients.

Statin therapy has been suggested to improve perioperative and long-term outcomes in various surgical populations, primarily through LDL cholesterol reduction as well as pleiotropic effects, such as enhanced endothelial function and anti-inflammatory actions. However, evidence specifically examining the impact of preoperative statin therapy on cardiovascular outcomes after LT remains limited, highlighting the need for further research in this population.

This study aimed to address the current knowledge gap by investigating the association between preoperative statin use and the incidence of major adverse cardiovascular events within 30 days after liver transplantation in liver transplant recipients. Secondary outcomes included overall mortality, early allograft dysfunction, acute kidney injury, length of stay in the intensive care unit, duration of mechanical ventilation, and myocardial injury after non-cardiac surgery within 3 and 30 days after transplantation.

Enrollment: 9,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

- Adult patients aged ≥18 years who underwent liver transplantation

Exclusion criteria

• Patients who underwent liver re-transplantation
• Patients with preoperative acute-on-chronic liver failure (ACLF)
• Patients with preoperative fulminant hepatic failure

Trial design

9,000 participants in 2 patient groups

Control group

Description:

Patients who did not receive preoperative statin therapy

Statin group

Description:

Patients who received preoperative statin therapy

Treatment:

Drug: Preoperative Statin Use